Danaher Q2 2026 EPS $1.23 (up 60% YoY), raises full-year adjusted EPS guidance to $8.45-$8.60

DANAHER CORP /DE/

2026-Q2 EPS reported $2.68 revenue$12,216,000,000

Net earnings $870M ($1.23 diluted EPS) up 60% YoY; adjusted EPS $1.94 up 8.0%.
Revenue $6.3B (+5.5% YoY); core revenue +3.0% (+4.5% ex-respiratory testing).
Operating cash flow $1.5B, free cash flow $1.3B.
Full-year 2026 adjusted EPS guidance raised to $8.45-$8.60 from $8.35-$8.55.
Bioprocessing orders grew mid-teens; Life Sciences had strongest quarter in years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.